Cartesian Therapeutics
RNAC
53 hedge funds and large institutions have $222M invested in Cartesian Therapeutics in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 7 reducing their positions, and 3 closing their positions.
243% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 7
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
10% more funds holding
Funds holding: 48 → 53 (+5)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.28% less ownership
Funds ownership: 2.12% → 1.84% (-0.28%)
5% less capital invested
Capital invested by funds: $235M → $222M (-$12.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$6.47M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.31M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.68M |
| 4 |
BlackRock
New York
|
+$1.39M |
| 5 |
Two Sigma Investments
New York
|
+$924K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVMCV
Polaris Venture Management Co V
Boston,
Massachusetts
|
-$5.26M |
| 2 |
Millennium Management
New York
|
-$3.61M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.38M |
| 4 |
DM
Deerfield Management
New York
|
-$1.92M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$632K |
RNAC Hedge Fund Activity: Q3 2017 in Review
53 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q3 2017, worth a combined $222M — down 5.2% from $235M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new RNAC positions and 3 closed out — a net gain of 5 holders — while 24 added to existing stakes and 7 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $6.47M. The largest seller was Polaris Venture Management Co V, cutting an estimated $5.26M.
- 53 institutional investors held Cartesian Therapeutics (RNAC) as of Q3 2017, up from 48 in Q2 2017.
- Funds reported $222M of Cartesian Therapeutics stock for Q3 2017, down 5.2% quarter-over-quarter.
- 8 funds opened new Cartesian Therapeutics positions in Q3 2017 and 3 closed out, a net change of +5 holders.
- The largest Cartesian Therapeutics buyer in Q3 2017 was Perceptive Advisors, an estimated $6.47M added.
- The largest Cartesian Therapeutics seller in Q3 2017 was Polaris Venture Management Co V, an estimated $5.26M sold.
Based on aggregated 13F filings for Q3 2017.